JP2017007956A5 - - Google Patents

Download PDF

Info

Publication number
JP2017007956A5
JP2017007956A5 JP2015122399A JP2015122399A JP2017007956A5 JP 2017007956 A5 JP2017007956 A5 JP 2017007956A5 JP 2015122399 A JP2015122399 A JP 2015122399A JP 2015122399 A JP2015122399 A JP 2015122399A JP 2017007956 A5 JP2017007956 A5 JP 2017007956A5
Authority
JP
Japan
Prior art keywords
interleukin
therapeutic
reducing agent
binding
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015122399A
Other languages
English (en)
Japanese (ja)
Other versions
JP6621252B2 (ja
JP2017007956A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2015122399A priority Critical patent/JP6621252B2/ja
Priority claimed from JP2015122399A external-priority patent/JP6621252B2/ja
Priority to EP16811690.3A priority patent/EP3311840B1/en
Priority to US15/736,203 priority patent/US20180193453A1/en
Priority to PCT/JP2016/067906 priority patent/WO2016204216A1/ja
Publication of JP2017007956A publication Critical patent/JP2017007956A/ja
Publication of JP2017007956A5 publication Critical patent/JP2017007956A5/ja
Application granted granted Critical
Publication of JP6621252B2 publication Critical patent/JP6621252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015122399A 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤 Active JP6621252B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2015122399A JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤
EP16811690.3A EP3311840B1 (en) 2015-06-17 2016-06-16 Treatment-resistance reducing agent for treatment-resistant cancer
US15/736,203 US20180193453A1 (en) 2015-06-17 2016-06-16 Treatment-resistance reducing agent for treatment-resistant cancer
PCT/JP2016/067906 WO2016204216A1 (ja) 2015-06-17 2016-06-16 治療耐性がんに対する治療耐性低減剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015122399A JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤

Publications (3)

Publication Number Publication Date
JP2017007956A JP2017007956A (ja) 2017-01-12
JP2017007956A5 true JP2017007956A5 (https=) 2018-08-02
JP6621252B2 JP6621252B2 (ja) 2019-12-18

Family

ID=57545648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015122399A Active JP6621252B2 (ja) 2015-06-17 2015-06-17 治療耐性がんに対する治療耐性低減剤

Country Status (4)

Country Link
US (1) US20180193453A1 (https=)
EP (1) EP3311840B1 (https=)
JP (1) JP6621252B2 (https=)
WO (1) WO2016204216A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356317B1 (ja) * 2017-06-05 2018-07-11 国立大学法人北海道大学 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び/又は治療のための医薬
WO2020027217A1 (ja) * 2018-07-31 2020-02-06 国立大学法人北海道大学 がんの治療及び/又は予防のための医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
MX378336B (es) * 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
JP2014520873A (ja) * 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン c−Fmsアンタゴニストの使用
RU2014136332A (ru) * 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
US10703813B2 (en) * 2014-12-19 2020-07-07 Universite De Nantes Anti IL-34 antibodies
BR112017020952A2 (pt) * 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição

Similar Documents

Publication Publication Date Title
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
CA2956871C (en) Compounds active towards bromodomains
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
PT4000608T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
HK1216083A1 (zh) 经动脉的药物递送
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
WO2015009726A3 (en) Medical uses of cd38 agonists
SI3069720T1 (sl) Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
LT3168214T (lt) Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas